All progestins are not created equal

Steroids

Volumn 68, Issue 10-13, 2003, Pages 879-890

  Stanczyk, Frank Z ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biologic activity; Metabolism; Pharmacokinetics; Potency; Progestin; Structure function relationships

Indexed keywords

ALGESTONE; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DEMEGESTONE; DESOGESTREL; DROSPIRENONE; DYDROGESTERONE; ETONOGESTREL; ETYNODIOL DIACETATE; GESTAGEN; GESTODENE; LEVONORGESTREL; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NESTERONE; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; NORGESTIMATE; PREGNANE DERIVATIVE; PRODRUG; PROGESTERONE; PROMEGESTONE; TESTOSTERONE; TIBOLONE; TRIMEGESTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONFERENCE PAPER; DRUG ACETYLATION; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG CONJUGATION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; FIRST PASS EFFECT; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REDUCTION; RELIABILITY;

ANIMALIA;

EID: 0345735762     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2003.08.003     Document Type: Conference Paper

References (39)

1. Stanczyk F.Z., Henzl M.R. Use of the name "progestin" Contraception. 64:2001;1-2.
2. Henzl MR. Contraceptive hormones and their clinical use. In: Yen SSC, Jaffe RE, editors. Reproductive endocrinology, physiology, pathophysiology, and clinical management. Philadelphia: WB Saunders; 1986. p. 643-82.
3. Stanczyk F.Z. Pharmacokinetics of progestogens. Int. Proc. J. 1:1989;11-20.
4. Stanczyk F.Z. Introduction: structure-function relationships, metabolism, pharmacokinetics and potency of progestins. Drugs Today. 32(Suppl. H):1996;1-14.
5. Stanczyk FZ. Structure-function relationships, potency and pharmacokinetics of progestogens. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. 2nd ed. Philadelphia: Lippincott, Williams and Wilkins; 1999. p. 105-24.
6. Stanczyk F.Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev. Endocr. Metab. Disord. 3:2002;211-224.
7. Edgren R.A., Stanczyk F.Z. Nomenclature of the gonane progestins. Contraception. 60:1999;313.
8. Stanczyk F.Z., Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 42:1990;67-96.
9. Mathrubutham M., Fotherby K. Medroxyprogesterone acetate in human serum. J. Steroid Biochem. 14:1981;783-786.
10. Kuhnz W., Huener A., Humpel M., Seifert W., Michaelis K. In vivo conversion of norethesterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception. 56:1997;379-385.
11. Stanczyk FZ. Pharmacokinetics of progesterone administered orally and parenterally. In: Sitruk-Ware R, Mishell Jr DR, editors. Progestins and antiprogestins in clinical practice. New York: Marcel-Dekker; 2000. p. 393-400.
12. Simon J.A., Robinson D.E., Andrews M.C., Hildebrand J.R. III, Rocci M.L. Jr., Blake R.E.et al. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil. Steril. 60:1993;26-33.
13. Sitruk-Ware R. Progestins in hormonal replacement therapy and prevention of endometrial disease. In: Sitruk-Ware R, Mishell Jr DR, editors. Progestins and anti-progestins in clinical practice. New York: Marcel Dekker; 2000. p. 269-87.
14. Hiroi M., Stanczyk F.Z., Goebelsmann U., Brenner P.F., Lumkin M.E., Mishell D.R. Jr. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids. 26:1975;373-386.
15. ®. A randomized, single-blind, triple cross-over bio-availability study in menopausal women. Maturitas. 18:1994;229-238.
16. Victor A., Johansson E.D. Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginally. Contraception. 14:1976;319-329.
17. Stanczyk F.Z., Mroszczak E.J., Ling T., Runkel R., Henzl M., Miyakawa I.et al. Plasma levels and pharmacokinetics of norethindrone and ethinylestradiol administered in solution and as tablets to women. Contraception. 28:1983;241-251.
18. Odlind V., Weiner E., Victor A., Johansson E.D.B. Plasma levels of norethindrone after single oral dose administration of norethindrone and lynestrenol. Clin. Endocrinol. 10:1979;29-38.
19. Back D.J., Brackenridge A.M., Crawford F.E., McIver M., Orme M.L.'E., Rowe P.H.et al. Kinetics of norethindrone in women. II. Single-dose kinetics. Clin. Pharmacol. Ther. 24:1978;448-453.
20. Humpel M., Wendr H., Dogs G., Weib C.H.R., Rietz S., Speck U. Intraindividual comparison of pharmacokinetic parameters of D-norgestrel, lynestrenol and cyproterone acetate in 6 women. Contraception. 16:1977;199-215.
21. Goebelsmann U., Hoffman D., Chiang S., Woutersz T. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. Contraception. 34:1986;341-351.
22. Stanczyk F.Z., Lobe R.A., Chiange S.T., Woutersz T.B. Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. Contraception. 41:1990;39-53.
23. Back D.J., Bates M., Breckenridge A.M., Hall J.M., MacIver M. Levonorgestrel and ethinylestradiol in women - studies with Ovran and Ovranette. Contraception. 23:1981;229-239.
24. Humpel M., Wendt H., Pommerenke G., Weib C.H.R., Speck U. Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first pass effect in women. Contraception. 17:1978;207-220.
25. Hasenack H.G., Bosch A.M.G., Kaar K. Serum levels of 3-ketodesogestrel after oral administration of desogestrel and 3-ketodesogestrel. Contraception. 33:1986;591-596.
26. Bergink W., Assendorp R., Koosterboer L., van Lier W., Voortman G., Qvist I. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin. Am. J. Obstet. Gynecol. 163:1990;2132-2137.
27. Back D.J., Grimmer S.F.M., Shenoy N., Orme M.L.E. Plasma concentrations of 3-ketodesogestrel after oral administration of desogestrel and intravenous administration of 3-ketodesogestrel. Contraception. 35:1987;619-626.
28. Orme M., Back D.J., Ward S., Green S. The pharmacokinetics of ethinyl estradiol in the presence and absence of gestodene and desogestrel. Contraception. 43:1991;305-316.
29. Tauber U., Tack J.W., Matthes H. Single dose pharmacokinetics of gestodene in women after intravenous and oral administration. Contraception. 40:1989;461-479.
30. McGuire J.L., Phillips A., Hahn D.W., Tolman E.L., Flor S., Kafrissen M.E. Pharmacologic and pharmacokinetic characteristics, of norgestimate. Am. J. Obstet. Gynecol. 163:1990;2127-2131.
31. Kuhnz W., Blode H., Mahler M. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing oral contraceptive to 12 women. Contraception. 47:1993;283-294.
32. Oettel M., Bervoas-Martin, Elger W., Golbs S., Hobe G., Kaufmann G.et al. A 19-norprogestin without a 17α-ethinyl group. I. Dienogest from a pharmacokinetic point of view. Drugs Today. 31:1995;499-516.
33. Blode H., Wuttke W., Loock W., Röll G., Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur. J. Contracept. Reprod. Health Care. 5:2000;256-264.
34. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 62:2000;29-38.
35. Juchem M, Pollow K. Binding of oral contraceptive progestins to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol 1990;2171-82.
36. Phillips A., Demarest D.W., Hahn F., Wong F., McGuire J.L. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception. 41:1990;399-410.
37. King R.J.B., Whitehead M.I. Assessment of the potency of orally administered progestins in women. Fertil. Steril. 46:1986;1062-1066.
38. Teichman AT. Levonorgestrel, vol. 43. Stuart-George Thieme Verlag; 1990.
39. Thorneycroft I.H., Stanczyk F.Z., Bradshaw K.D., Ballagh S.A., Nichols M., Weber M.E. Effect of low-dose contraceptives on androgenic markers and acne. Contraception. 60:1999;255-262.